Skin Test Documentation Checklist for Allergy Practices (Prick and Intradermal)

The short answer: a complete skin-test record shows why the patient was

tested, which medications could have blunted the result, which extracts and

device were used, that the positive and negative controls behaved, what each

site measured in millimetres and when, and who confirmed and signed it. The

joint AAAAI/ACAAI practice parameters for allergy diagnostic testing put it

plainly: both erythema and wheal "should be measured in a standardized manner

and the method(s) of measuring should be recorded."

The checklist below follows those parameters. Use it to audit your own skin

testing form or template. Your practice's protocol and your physicians'

judgement come first; this is a documentation aid, not a clinical protocol.

Before the test

• [ ] Indication. The history and exposures that justify testing, and which

allergens are being tested and why. The parameters tie interpretation

to the history and physical: a positive test alone "does not establish

whether clinical sensitivity currently is present."

• [ ] Retesting reason, if this isn't the first panel. The parameters list

changing symptoms, new exposures and 3 to 5 years of venom

immunotherapy as typical indications.

• [ ] Medications that suppress skin tests, with the last dose. The

parameters advise stopping first-generation antihistamines 24 to 72

hours before testing (hydroxyzine up to 96 hours), note that other

non-sedating antihistamines may need up to a week, that tricyclic

antidepressants may need 7 to 14 days, and that H2 antagonists should

stop 24 hours before. Chronic high-dose oral corticosteroids and potent

topical corticosteroids on the test site can also suppress reactions.

• [ ] Beta-blockers or MAO inhibitors. The parameters call for special

precautions in these patients, so record that they were checked.

• [ ] Pregnancy status, where relevant. The parameters reserve testing in

pregnancy for results with "substantial and immediate therapeutic

implications."

• [ ] Skin at the test site. No testing on active dermatitis; if

dermatographism is present, results "must be interpreted with caution."

Record what you saw.

Setting up the panel

• [ ] Method and device. Prick/puncture or intradermal, and the device

used. The parameters note that results depend on the tester, the device,

and the depth, force, duration and angle of application.

• [ ] Test site. Upper back or volar forearm, and a site map or numbering

that ties each mark on the skin to an allergen.

• [ ] Each extract. Name, concentration and, ideally, lot and expiry.

Extract potency falls with time, dilution and heat, and the parameters

ask practices to check expiration dates regularly.

• [ ] Who placed the panel, and at what time. Readings are timed from

application.

Controls

• [ ] Positive control (histamine) and negative control (diluent) placed and

recorded. The parameters say both are needed "to properly interpret

allergy skin tests."

• [ ] Histamine read at 15 minutes, when it reaches peak reactivity.
• [ ] A note when the controls make the panel hard to read: a weak

histamine response, or a reactive diluent. That note protects the

interpretation later.

Reading prick/puncture tests

• [ ] Read at the peak, usually 15 to 20 minutes after application, and

record the reading time.

• [ ] Wheal and erythema in millimetres, measured the same way every time,

with the measuring method written down.

• [ ] Positive by the parameters' threshold: a wheal at least 3 mm larger

than the diluent control done at the same time, with equivalent

erythema.

• [ ] Who read it. The parameters ask practices to validate tester

proficiency and run ongoing staff in-service training, which is hard to

do if the record doesn't say who measured what.

Intradermal tests

• [ ] Why intradermal: usually a negative or equivocal prick test despite a

compatible history.

• [ ] Starting dilution. The parameters suggest starting 100- to 1,000-fold

more dilute than the prick solution after a negative prick test.

• [ ] Wheal and erythema diameters, measured and recorded.
• [ ] A caution on small reactions. Any reaction larger than the negative

control may indicate specific IgE, but intradermal testing is less

specific, so small positives may not be clinically relevant.

Safety and sign-off

• [ ] Any adverse reaction (large local or systemic), what was given, and

the observation period. The parameters recommend that full emergency

equipment and drugs be on hand.

• [ ] Interpretation in context. Results correlated with the history, and

the plan (avoidance, immunotherapy candidacy, further testing) written

by the clinician.

• [ ] Clinician signature, with the panel results visible alongside the

visit note rather than on a separate sheet.

Where the minutes go

Most of this checklist isn't hard. It's repetitive. A 40-site panel means 40

numbers transcribed, two controls checked, and a note that has to agree with

the form. That transcription and reconciliation is where skin-test visits

slow down at sign-off.

Medora was built for that part of the work, together with a working allergy

practice:

• The nurse photographs the prick or intradermal panel. Medora finds each test

site by the number written beside it and drafts each wheal size from the

photo, measured against the printed ruler card.

• When Medora can't confirm the scale or isn't sure about a site, it flags it

for the nurse instead of guessing. The nurse checks what's flagged,

corrects the draft and confirms the rest. Nothing is recorded as "no

reaction" until a person confirms it.

• The draft asks the nurse for the histamine and saline controls first.
• Your practice's grading rules classify the results. The review screen shows

how each result was made (drafted by Medora, confirmed by the nurse, signed

by the clinician), with an audit trail.

• The confirmed results sit alongside the allergy note that Medora Copilot

drafts from the visit, so the clinician reviews both together and signs.

In a 60-day pilot at Allergy Affiliates, provider sign-off per skin-test visit

went from 18 minutes to 4

(the case study).

Frequently asked questions

What should a skin test record include?

The indication, medications that could suppress the test (with the last

dose), skin condition at the site, method and device, each extract and its

concentration, positive and negative controls, reading times, wheal and

erythema in millimetres with the measuring method, who read it, any reaction,

and the clinician's interpretation and signature.

When should skin prick tests be read?

The AAAAI/ACAAI practice parameters say prick/puncture tests should be read at

the peak of the reaction, usually 15 to 20 minutes after application, and that

histamine controls should be read at 15 minutes.

What counts as a positive skin prick test?

The parameters treat a wheal at least 3 mm larger than the diluent control,

with equivalent erythema, as evidence of allergen-specific IgE. A positive

test still has to be read against the history.

Should skin test results be recorded in millimetres or as a plus grade?

The parameters ask for wheal and erythema to be measured in a standardized

way, with the method recorded. Many practices record millimetres and then

apply their own grading rules; Medora supports that approach, with the

practice's grading rules classifying the confirmed measurements.

Does Medora read skin tests?

No. Medora drafts each wheal size from the photo and flags anything it's

unsure of. The nurse confirms the results and the clinician signs. Nothing is

final without a person.

Try it on your own visits

• See how Medora handles allergy documentation
• Start the 7-day free trial of Medora Scribe
• Book a demo of skin testing in Medora
• Read the full buyer's guide

*Source: Joint AAAAI/ACAAI Practice Parameters for Allergy Diagnostic Testing,

summary statements on immediate-hypersensitivity skin testing. Check your own

protocol and the current parameters before changing practice.*